Scarica l'app Stockscreener
64.56
2.77%
-1.875
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$66.43
Aprire:
$66
Volume 24 ore:
561.88K
Relative Volume:
0.68
Capitalizzazione di mercato:
$4.02B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
24.64
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
-2.06%
1M Prestazione:
+9.38%
6M Prestazione:
+37.78%
1 anno Prestazione:
+45.57%
Intervallo 1D:
$64.52
$66.53
Intervallo di 1 settimana:
$63.82
$68.26
Portata 52W:
$33.31
$68.26
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
64.57 | 4.13B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.64 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.96 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.86 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
773.12 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.13 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Springfield News-Leader
Sentiment analysis tools applied to Protagonist Therapeutics Inc.2025 Trading Volume Trends & Daily Stock Trend Watchlist - newser.com
Why Protagonist Therapeutics Inc. stock could be next big winner2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com
Can Protagonist Therapeutics Inc. stock hit record highs againJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com
Short interest data insights for Protagonist Therapeutics Inc.M&A Rumor & High Accuracy Swing Trade Signals - newser.com
Historical volatility pattern of Protagonist Therapeutics Inc. visualizedLong Setup & Real-Time Buy Signal Notifications - newser.com
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.1%What's Next? - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $68.26, Up 103% - Markets Mojo
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Corpus Christi Caller-Times
What analysts say about Protagonist Therapeutics Inc stockGlobal Market Influence & Free Discover Massive Upside Stocks - earlytimes.in
What drives Protagonist Therapeutics Inc stock priceMarket Liquidity Analysis & Market Monitoring and Alerts - earlytimes.in
Protagonist Therapeutics (MEX:PTGX) Tariff Resilience Score : 5/10 (As of Sep. 27, 2025) - GuruFocus
Protagonist Therapeutics stock reaches all-time high at 66.7 USD - Investing.com India
Protagonist Therapeutics stock reaches all-time high at 66.7 USD By Investing.com - Investing.com Canada
Protagonist Therapeutics Hits New 52-Week High of $66.70, Up 98.82% - Markets Mojo
7,530 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Palumbo Wealth Management LLC - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $65.08 - Markets Mojo
Assenagon Asset Management S.A. Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in Stock - MarketBeat
Waddill, Protagonist Therapeutics director, sells $257k in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $64.59, Up 94.48% - Markets Mojo
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Exchange Traded Concepts LLC - MarketBeat
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Cincinnati Enquirer
Voya Investment Management LLC Has $2.89 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Strs Ohio Takes $919,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency - Lubbock Avalanche-Journal
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's Why - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Barclays - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $63.30 - Markets Mojo
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $68.08 - MarketBeat
Protagonist Therapeutics' (PTGX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Barclays - MarketBeat
Protagonist Therapeutics Hits New 52-Week High at $62.21 - Markets Mojo
Aug Big Picture: Will Protagonist Therapeutics Inc benefit from AI trendsMarket Volume Summary & Precise Entry and Exit Recommendations - khodrobank.com
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):